Bonus BioGroup Ltd (BBIXF PINK) stock market data APIs
$0.0001
0(0%)
as of July 2, 2025
Try our APIs with
free plan!
Bonus BioGroup Ltd Financial Data Overview
Price chart is built with
Anychart
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of bone augmentation in osteoporosis patients. It also develops MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS which is in phase III clinical trial, as well as in preclinical stage for the treatment of other inflammations and tissue damage, including chronic kidney diseases, osteoarthritis, and cytokine release syndrome. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is headquartered in Haifa, Israel.
Prev. Close
0.0001
Open
0.0001
High
0.0001
Low
0.0001
52 wk Range
0.0001-0.05
Market Cap
67 607 K
Shares Outstanding
1 168 M
EPS
-0.0014
Beta
0.892
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bonus BioGroup Ltd data using free add-ons & libraries
Get Bonus BioGroup Ltd Fundamental Data
Bonus BioGroup Ltd Fundamental data includes:
- Net Revenue:
- EBITDA: -26 203 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-12-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bonus BioGroup Ltd News
New
Bonus BioGroup's COVID Drug - MesenCure - Can Help a Life-threatening Complication Seen in Cancer Patients
Bonus BioGroup (TASE: BONS), a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, has discovered that its C...
POET Technologies to Report Full Year 2021 Financial Results on April 26
POET Technologies Inc. Management to Host Business Update Conference Call on April 27 TORONTO, April 21, 2022 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Ventur...
Bonus BioGroup Submits Outstanding Phase-II Trial Results for MesenCure, a Treatment for Severe COVID-19, to the Israeli Ministry of Health
Tel Aviv, Israel--(Newsfile Corp. - January 18, 2022) - Bonus BioGroup (TASE: BONS) or "the Company", a clinical-stage Israeli biotechnology company engaged in the research and development of biomedic...
Bonus BioGroup Reports 94% Survival Rate for Severe COVID-19 Cases in the Phase II Clinical Trial of its MesenCure Treatment
Tel Aviv, Israel--(Newsfile Corp. - December 2, 2021) - Bonus BioGroup or (TASE: BONS) "the Company", a clinical-stage Israeli biotechnology company engaged in the research and development of biomedic...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
